- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.08. | Acrivon beruft Michaela Levin zum Chief Business Officer | 2 | Investing.com Deutsch | ||
| 31.08. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer | 211 | GlobeNewswire (Europe) | WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing... ► Artikel lesen | |
| 12.08. | Acrivon Therapeutics GAAP EPS of -$0.43 beats by $0.07 | 6 | Seeking Alpha | ||
| 12.08. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 20 | SEC Filings | ||
| 05.08. | Acrivon advances cancer drug ACR-2316 to dose expansion phase | 4 | Investing.com | ||
| 05.08. | Acrivon Therapeutics, Inc: Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study | 289 | GlobeNewswire (Europe) | Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen... ► Artikel lesen | |
| 17.06. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 15 | SEC Filings | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit | 17 | GlobeNewswire (USA) | ||
| 15.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 14.05. | Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress | 25 | Investing.com | ||
| 14.05. | Acrivon: Citizens bestätigt Rating nach Fortschritten bei Krebsstudie | 56 | Investing.com Deutsch | ||
| 13.05. | Acrivon Therapeutics GAAP EPS of -$0.49 beats by $0.03 | 2 | Seeking Alpha | ||
| 13.05. | Acrivon Therapeutics, Inc: Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts | 288 | GlobeNewswire (Europe) | The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms... ► Artikel lesen | |
| 13.05. | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.04. | Acrivon Therapeutics, Inc: Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities | 13 | GlobeNewswire (USA) | ||
| 24.03. | Citizens bekräftigt Rating für Acrivon nach Fortschritten bei Studie zu Endometriumkrebs | 20 | Investing.com Deutsch | ||
| 24.03. | Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress | 9 | Investing.com | ||
| 19.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | 339 | GlobeNewswire (Europe) | Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation... ► Artikel lesen | |
| 13.11.25 | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | 179 | GlobeNewswire (Europe) | Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,75 | +1,32 % | Biontech: Viel Lob für die Ergebnisse | Auf einem Lungenkrebs-Kongress stellt Biontech zwei neue Studienergebnisse vor. Dabei geht es einerseits um Gotistobart. Hier zeigt sich fast eine Verdopplung der Überlebenszeit im Vergleich zur Standardchemotherapie.... ► Artikel lesen | |
| MODERNA | 146,96 | +9,67 % | Moderna und BioNTech lassen Corona endgültig hinter sich | Aus dem alten Duell der beiden Corona-Gewinner ist ein neuer Wettbewerb geworden. Moderna erlebt nach überzeugenden Phase-3-Daten für eine personalisierte Krebstherapie eine spektakuläre Neubewertung.... ► Artikel lesen | |
| AMGEN | 342,35 | +1,98 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 9,090 | +3,41 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 193,00 | +2,85 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| NANOREPRO | 1,680 | -1,75 % | NanoRepro-Aktie: Ist das der beste Nano Cap? | Die NanoRepro AG möchte eine breit aufgestellte Consumer-Health-Plattform entwickeln. Die Aktie ist nach ihren Höhenflug zur Jahresmitte wieder deutlich zurückgekommen. Wie geht es jetzt weiter? Ambitionierte... ► Artikel lesen | |
| VIVOSIM LABS | 0,248 | +11,20 % | VivoSim Labs, Inc.: VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs | ||
| OCUGEN | 0,902 | -2,80 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,058 | -1,76 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| CLINUVEL | 5,126 | +0,79 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INFLARX | 1,838 | +0,77 % | InflaRx N.V.: InflaRx to Host Virtual Capital Markets Day | ||
| INTELLIA THERAPEUTICS | 10,680 | +0,95 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 68,52 | +1,12 % | Goldman Sachs startet Coverage für Tempus AI Aktie mit "Neutral"-Rating | ||
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report |
ACRIVON THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,910 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.